immuno-oncology

News

Alligator pancreatic cancer drug 'nearly doubles' survival

Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.<

News

vaccine vial held by hands in surgical green gloves

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta

News

Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

News

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

News

ESMO: GSK, iTeos bring some optimism back to TIGIT

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea

Alligator pancreatic cancer drug 'nearly doubles' survival

MSD, Moderna start phase 3 adjuvant lung cancer trial

Transgene cervical cancer shot misses the mark in phase 2

MSD hits a hurdle with its LAG-3 programme

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

ESMO: GSK, iTeos bring some optimism back to TIGIT

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

immuno-oncology

Editor's Picks